Menu
Back to Journals » Biologics: Targets and Therapy » Volume 13
Original Research
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 12,472 | Dovepress* | 10,714+ | 787 | 11,501 | |
| PubMed Central* | 1,758 | 175 | 1,933 | ||
| Totals | 12,472 | 962 | 13,434 | ||
| *Since 25 November 2019 | |||||
View citations on PubMed Central and Google Scholar